NCT06843304Recruiting
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
Source: ClinicalTrials.gov · Last updated 20 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Diabetic nephropathy is one of the most severe microvascular complications of diabetes and a major cause of premature death and disability. It has become a leading cause of end-stage renal failure both in China and worldwide, consuming substantial medical resources. The establishment of a comprehensive regulatory system for the development and progression of diabetic nephropathy is a critical need for effective prevention and control. However, there is a lack of representative cohorts covering the entire disease cycle of diabetic nephropathy both domestically and internationally, creating technical bottlenecks in comprehensively describing its developmental patterns. This project aims to expand and integrate existing large-sample natural population cohorts and prospective follow-up cohorts covering the entire disease cycle of diabetes and diabetic nephropathy. It will construct a panoramic life database to identify risk factors, clinical phenotypes, and multimodal biomarkers at different disease stages. By integrating multi-organ interactions (e.g., kidney, eye), the project will establish novel imaging and functional assessment technologies for microvascular complications. Utilizing artificial intelligence to process multimodal medical data, it will build and validate risk prediction models and evaluation systems for the entire disease cycle of diabetic nephropathy. The project will develop effective intelligent prevention and treatment strategies for diabetic nephropathy, promote the adoption of new technologies, and establish a medical quality control system to provide services for medical institutions. Ultimately, it aims to improve and sustain medical quality, reducing the incidence of end-stage renal disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 20 Feb 2025
- Start date
- 1 Jan 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Chinese PLA General Hospital
- Diseases
- Chronic kidney disease
- NCT number
- NCT06843304
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 1 Jan 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Combined with autoimmune diseases and tumors
- Type 2 diabetes patients undergoing renal biopsy
- Gestational diabetes mellitus, special type diabetes mellitus
- Patients with hereditary kidney disease
- Combined with autoimmune diseases
Other
- Incomplete medical records
- Lack of fundus microvascular examination or new imaging technology examination results data
- Diabetic nephropathy The indicators in the comprehensive assessment model of the risk of renal progression could not be obtained
- There were pregnancy plans in the study period
Who the study is looking for
- Age ≥18 years old, gender is not limited
- Diagnosed with type 2 diabetes
- A history of type 2 diabetes for more than 5 years
- Negative proteinuria
- Creatinine is normal
- Good compliance, voluntarily sign informed consent
- Age ≥18 years old, gender is not limited
- Diagnosed with type 2 diabetes
- Kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency)
- Have undergone renal puncture biopsy and have complete renal pathological diagnosis data
- Sign informed consent voluntarily
Criteria the registry did not label
- T2DM
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.